Product image of Latanoprost Stulln (Latanoprost) supplied by GNH India

Latanoprost Stulln

Active Ingredient:
Latanoprost
Origin:
EU

Latanoprost Stulln (Latanoprost)

Latanoprost, the active ingredient in Latanoprost Stulln, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It reduces intra‑ocular pressure by enhancing uveoscleral outflow, making it a cornerstone therapy for patients with primary open‑angle glaucoma and ocular hypertension.

GNH India supplies Latanoprost Stulln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards, offering batch‑to‑batch traceability and supporting regulatory compliance for importers across multiple regions.

Manufacturer / TM Owner

Pharma Stulln Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma and ocular hypertension.

  • Primary open-angle glaucoma: reduces intra‑ocular pressure and helps prevent optic nerve damage.
  • Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma.
  • Secondary open-angle glaucoma: provides pressure reduction similar to primary disease.
  • Pseudoexfoliative glaucoma: achieves intra‑ocular pressure control in this subtype.
  • Post‑laser trabeculoplasty management: maintains lowered pressure after laser procedures.

How It Works

  • Latanoprost binds to prostaglandin F (FP) receptors in the ciliary body, activating a cascade that remodels the extracellular matrix and increases uveoscleral outflow of aqueous humor. The enhanced outflow lowers intra‑ocular pressure, addressing the primary pathogenic factor in open‑angle glaucoma and ocular hypertension.

Side Effects

Common Side Effects

  • Eye redness: mild conjunctival hyperemia.
  • Eye irritation or burning sensation upon instillation.
  • Increased eyelash growth (hypertrichosis).
  • Darkening of the iris (gradual pigmentation change).
  • Blurred vision: transient visual disturbance.
  • Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

  • Ocular inflammation (uveitis or iritis).
  • Macular edema: swelling of the central retina.
  • Severe allergic reaction: swelling, itching, or rash.
  • Persistent eye pain or discomfort.
  • Sudden loss of vision.
  • Corneal ulceration or infection.

Precautions & Warnings

Before initiating therapy, evaluate ocular health and monitor intra‑ocular pressure regularly.

  • Assess corneal health: avoid use in patients with active corneal disease.
  • Screen for ocular infections: do not use during active bacterial or viral eye infections.
  • Caution in patients with a history of uveitis: monitor for inflammation.
  • Advise patients to avoid contact lens wear for at least 15 minutes after instillation.
  • Store at room temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Latanoprost may interact with other ocular or systemic agents that affect intra‑ocular pressure or ocular surface.

Major Interactions (Avoid)

  • Concurrent use of other prostaglandin analog eye drops: additive iris pigmentation and eyelash changes.
  • Combination with ocular corticosteroids: increased risk of cataract formation.

Moderate Interactions (Monitor Closely)

  • Beta‑blocker eye drops: may enhance systemic absorption leading to cardiovascular effects.
  • Carbonic anhydrase inhibitor eye drops: additive pressure‑lowering effect, monitor for hypotony.
  • Systemic non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce prostaglandin efficacy.
  • Anticholinergic agents: potential for reduced tear production, monitor ocular surface comfort.

Frequently Asked Questions

Latanoprost Stulln is an ophthalmic solution containing the prostaglandin analog latanoprost. It is prescribed to lower intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension, helping to prevent optic nerve damage and preserve visual function.

Latanoprost binds to prostaglandin F (FP) receptors in the eye’s ciliary body, triggering remodeling of the extracellular matrix. This process increases the uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Latanoprost Stulln is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the individual prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, latanoprost often provides greater pressure‑lowering efficacy with a convenient dosing schedule, though individual response may vary.

Latanoprost Stulln should be stored at room temperature below 25 °C, protected from moisture and direct sunlight. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contaminated.

The medication is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Patients should wash their hands before instillation, avoid touching the tip of the bottle to the eye or any surface, and wait a few minutes before applying other eye medications.

Serious but rare risks include ocular inflammation such as uveitis, macular edema, severe allergic reactions, and sudden loss of vision. Any sudden eye pain, visual changes, or signs of infection should prompt immediate medical evaluation.

Patients with active ocular infections, severe corneal disease, known hypersensitivity to latanoprost or any component of the formulation, and those who have had a recent intra‑ocular surgery without physician approval should avoid using Latanoprost Stulln.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT